Sichuan Defeng Pharmaceutical Co., Ltd.

Sichuan Defeng Pharmaceutical Co., Ltd. is located in Meishan Economic Development Zone New Area, Sichuan Province. It is a wholly-owned subsidiary of Yifan Pharmaceutical Co., Ltd., a listed company. With a registered capital of RMB 130 million and a site area of 73 mu, the company focuses on the R&D and production of pharmaceutical products in fields including dermatology, pediatrics, and gynecology. It also provides contract manufacturing services for various dosage forms such as granules, tablets, and syrups. The company has established innovation platforms including a provincial-level enterprise technology center. Adhering to the strategy of integrating generic drug development with innovation-driven development, it has built a comprehensive R&D system and professional talent development system. The company has obtained 11 authorized invention patents, several of which have addressed domestic technological gaps, while some core products have achieved import substitution. It possesses 80 drug manufacturing approvals and 13 exclusive drug varieties/formulations, including 7 products listed in the National Medical Insurance Catalogue and 2 products listed in the National Essential Medicines List, demonstrating strong competitive advantages in its core fields. Sichuan Defeng Pharmaceutical Co., Ltd.Sichuan Defeng Pharmaceutical Co., Ltd. is located in Meishan Economic Development Zone New Area, Sichuan Province. It is a wholly-owned subsidiary of Yifan Pharmaceutical Co., Ltd., a listed company. With a registered capital of RMB 130 million and a site area of 73 mu, the company focuses on the R&D and production of pharmaceutical products in fields including dermatology, pediatrics, and gynecology. It also provides contract manufacturing services for various dosage forms such as granules, tablets, and syrups.The company has established innovation platforms including a provincial-level enterprise technology center. Adhering to the strategy of integrating generic drug development with innovation-driven development, it has built a comprehensive R&D system and professional talent development system. The company has obtained 11 authorized invention patents, several of which have addressed domestic technological gaps, while some core products have achieved import substitution. It possesses 80 drug manufacturing approvals and 13 exclusive drug varieties/formulations, including 7 products listed in the National Medical Insurance Catalogue and 2 products listed in the National Essential Medicines List, demonstrating strong competitive advantages in its core fields.